Skip to main content
Publications
Hall RE, Tusevljak N, Wu CF, Ibrahim Q, Schulze K, Khan AM, Desai D, Awadalla P, Broet P, Dummer TJB, Hicks J, Tardif JC, Teo KK, Vena J, Lee D, Friedrich M, Anand SS, Tu JV. The Canadian alliance for healthy hearts and minds: how well does it reflect the Canadian population? CJC Open. 2020 Jul 22;2(6):599-609. doi: 10.1016/j.cjco.2020.07.013
Willis TA, Hartley S, Glidewell L, Farrin AJ, Lawton R, McEachan RRC, Ingleson E, Heudtlass P, Collinson M, Clamp S, Hunter C, Ward V, Hulme C, Meads D, Bregantini D, Carder P, Foy R. Action to support practices implement research evidence (ASPIRE): protocol for a cluster-randomised evaluation of adaptable implementation packages targeting 'high impact' clinical practice recommendations in general practice. Implement Sci. 2016 Feb 29;11(25). doi: 10.1186/s13012-016-0387-5
Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res. 2011 Jun 15;17(12):4063-70. doi: 10.1158/1078-0432.CCR-10-2599
LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox A, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res. 2003 Jun 1;9(6):2040-8.
